For colorectal cancer, Bacac et al. and Lehmann et al. have reported the development of a novel T cell bispecific CEA-TCB (T cell bispecific) antibody (cibisatamab, RG7802, RO6958688) for targeting carcinoembryonic antigen (CEA) on tumor cells and CD3 on T cells (10,11). This evidence concerns the gene CEACAM5 and neoplasm.